Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The ESMO Asia Congress is the annual event where global and Asian cancer professionals come together, to present and discuss the latest scientific and clinical advances across the entire field of oncology, of relevance at a global level, and for the Asia-Pacific region.

ESMO Asia 2022

ESMO Asia 2022
02–04 December 2022 | Singapore

ESMO Asia 2022

ESMO Asia 2022
02–04 December 2022 | Singapore
The ESMO Asia Congress is the annual event where global and Asian cancer professionals come together, to present and discuss the latest scientific and clinical advances across the entire field of oncology, of relevance at a global level, and for the Asia-Pacific region.
Latest developments in immunotherapy for advanced/recurrent endometrial cancer 5:23
Latest developments in immunotherapy for advanced/recurrent endometrial cancer
Domenica Lorusso • 5 Dec 2022
Highlights from ESMO Asia 2022 in HCC 1:09
Highlights from ESMO Asia 2022 in HCC
Stephen L. Chan • 5 Dec 2022
Phase II trial of cabozantinib for patients with HCC previously treated with IO 2:58
Phase II trial of cabozantinib for patients with HCC previously treated with IO
Stephen L. Chan • 5 Dec 2022
HIMALAYA trial: Asian subgroup results 2:35
HIMALAYA trial: Asian subgroup results
Stephen L. Chan • 5 Dec 2022
Identifying patients with HCC who will respond best to IO 1:16
Identifying patients with HCC who will respond best to IO
Stephen L. Chan • 5 Dec 2022
Improving guidance on choice of first-line therapy for patients with HCC 1:09
Improving guidance on choice of first-line therapy for patients with HCC
Mara Persano • 1 Dec 2022
Unmet needs in immunotherapy for hepatocellular carcinoma 1:21
Unmet needs in immunotherapy for hepatocellular carcinoma
Mara Persano • 1 Dec 2022
Real-world outcomes of patients with HCC treated with lenvatinib vs. atezolizumab plus bevacizumab 4:03
Real-world outcomes of patients with HCC treated with lenvatinib vs. atezolizumab plus bevacizumab
Mara Persano • 1 Dec 2022
Improving responses to immunotherapy for patients with endometrial cancer 1:42
Improving responses to immunotherapy for patients with endometrial cancer
Domenica Lorusso • 5 Dec 2022
ESMO Asia 2022: Importance of successful collaboration to improve guidelines around the world 1:05
ESMO Asia 2022: Importance of successful collaboration to improve guidelines around the world
Domenica Lorusso • 5 Dec 2022
Improving outcomes for patients with head and neck cancer 2:47
Improving outcomes for patients with head and neck cancer
Avinash Khadela • 29 Nov 2022
The EXTREME regimen for head and neck cancer 1:22
The EXTREME regimen for head and neck cancer
Avinash Khadela • 29 Nov 2022
EXTREME regimen vs. cetuximab + cisplatin + paclitaxel for recurrent/metastatic head and neck cancer 2:54
EXTREME regimen vs. cetuximab + cisplatin + paclitaxel for recurrent/metastatic head and neck cancer
Avinash Khadela • 29 Nov 2022
Improving cancer registry systems in Asia 3:36
Improving cancer registry systems in Asia
Tomohiro Matsuda • 24 Nov 2022
Challenges of data sharing between healthcare systems in Asian countries 2:01
Challenges of data sharing between healthcare systems in Asian countries
Tomohiro Matsuda • 24 Nov 2022
RARECAREnet-Asia: research into epidemiology of rare cancers in Asia 2:32
RARECAREnet-Asia: research into epidemiology of rare cancers in Asia
Tomohiro Matsuda • 24 Nov 2022
The content of VJOncology is intended for healthcare professionals